More importantly, western blot and tumor immunohistochemical staining assays demonstrated decreased expression of MMP-2, MMP-3, and MMP-9 in the primary 4T1 tumor after D-NPBB94/C-NPBB94 treatment (Fig. 4d–f), which further confirmed its excellent therapeutic activity. This evidence concerns the gene MMP9 and neoplasm.